Skip to main content

Evaluating Outpatient Teclistamab Administration in Multiple Myeloma With Robert Rifkin, MD, FACP

Oncology Data Advisor® · Evaluating Outpatient Teclistamab Administration in Multiple Myeloma: Robert Rifkin, MD At the recent American Society of Hematology (ASH) Annual Meeting, Dr. Robert Rifkin, MD, FACP, a Board-Certified Medical Oncologist and Hematologist at the Rocky Mountain Cancer Centers in Denver, Colorado, sat down with Oncology Data Advisor to discuss his study and presentation on the OPTEC trial, in which administration of the bispecific antibody teclistamab will be eva...

Continue reading